

## UNITED STATES NUCLEAR REGULATORY COMMISSION

REGION I 2100 RENAISSANCE BOULEVARD, SUITE 100 KING OF PRUSSIA, PENNSYLVANIA 19406-2713

January 17, 2013

Docket No. 03012570 License No. 47-05322-02

Control No. 577287

Lisa Schatz, Pharm.D. Senior Clinical Director Wheeling Hospital, Inc. 1 Medical Park Wheeling, WV 26003-6300

SUBJECT: WHEELING HOSPITAL, INC., ACCEPTANCE OF NOTIFICATION,

AMENDMENT NOT NEEDED, CONTROL NO. 577287

Dear Dr. Schatz:

In your letter dated April 2, 2012, you requested addition of Radium-223 dichloride (<sup>223</sup>RaCl2) to your license to be used under the supervision of Dr. Gregory Merrick. Please note that on January 10, 2013, the Nuclear Regulatory Commission issued a letter documenting the review of this issue (ML12349A275) and indicated the following:

- 1. Licensing under Title 10 of the Code of Federal Regulations (10CFR) Part 35, Subpart E "Unsealed Byproduct Material Written Directive Required" is appropriate.
- 2. Physicians who are approved for the use of any beta emitter or any photon-emitting radionuclide with a photon energy less than 150 keV under 10 CFR 35.390 "Training for use of unsealed byproduct material for which a written directive is required" or 10 CFR 35.396 "Training for the parenteral administration of unsealed byproduct material requiring a written directive" can be authorized for the medical use of <sup>223</sup>RaCl<sub>2</sub>.
- 3. The current methods of distribution (unit dosages) preclude the need for end users to manipulate 223RaCl<sub>2</sub>.

In addition, we understand that the dosage is prepared for use in research in accordance with an Investigational new drug (IND) protocol accepted by FDA as required by 10 CFR 35.300.

Since your license already authorizes full use under 10 CFR 35.300 and authorized users for these uses, an amendment is not needed. Your letter is accepted as notification that you plan to conduct this activity. No further correspondence on this subject is necessary.

The NRC's Safety Culture Policy Statement became effective in June 2011. While a policy statement and not a regulation, it sets forth the agency's *expectations* for individuals and organizations to establish and maintain a positive safety culture. You can access the policy statement and supporting material that may benefit your organization on NRC's safety culture Web site at <a href="http://www.nrc.gov/about-nrc/regulatory/enforcement/safety-culture.html">http://www.nrc.gov/about-nrc/regulatory/enforcement/safety-culture.html</a>. We

L. Schatz 2

strongly encourage you to review this material and adapt it to your particular needs in order to develop and maintain a positive safety culture as you engage in NRC-regulated activities.

Thank you for your cooperation.

Sincerely,

Original signed by Penny Lanzisera

Penny Lanzisera Senior Health Physicist Medical Branch Division of Nuclear Materials Safety

CC:

Wayne Butler, Ph.D., Radiation Safety Officer

L. Schatz 3

DOCUMENT NAME: G:\WordDocs\Current\Lic Cvr Letter\L47-05322-02.577287.doc

**SUNSI Review Complete:** PLanzisera

After declaring this document "An Official Agency Record" it will be released to the Public.

To receive a copy of this document, indicate in the box: "C" = Copy w/o attach/encl "E" = Copy w/ attach/encl "N" = No copy

OFFICE	DNMS/RI	N	DNMS/RI	DNMS/RI		
NAME	PLanzisera / <b>PL</b> /					
DATE	1-17-13					

OFFICIAL RECORD COPY